Orchestra BioMed Valuation
| OBIO Stock | 4.51 0.16 3.68% |
At this time, the company appears to be overvalued. Orchestra BioMed Holdings holds a recent Real Value of USD3.96 per share. The prevailing price of the company is USD4.51. Our model determines the value of Orchestra BioMed Holdings from analyzing the company fundamentals such as Current Valuation of 104.37 M, shares owned by insiders of 21.81 %, and Return On Equity of -0.92 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Orchestra BioMed's valuation include:
Price Book 3.6663 | Enterprise Value | Enterprise Value Ebitda (1.81) | Price Sales 64.768 | Enterprise Value Revenue 39.4281 |
Overvalued
Today
Please note that Orchestra BioMed's price fluctuation is very risky at this time. Calculation of the real value of Orchestra BioMed Holdings is based on 3 months time horizon. Increasing Orchestra BioMed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Orchestra BioMed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Orchestra Stock. However, Orchestra BioMed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.51 | Real 3.96 | Target 15.67 | Hype 4.51 | Naive 5.13 |
The intrinsic value of Orchestra BioMed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Orchestra BioMed's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Orchestra BioMed Holdings helps investors to forecast how Orchestra stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Orchestra BioMed more accurately as focusing exclusively on Orchestra BioMed's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Orchestra BioMed's intrinsic value based on its ongoing forecasts of Orchestra BioMed's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Orchestra BioMed's closest peers.
Orchestra BioMed Cash |
|
Orchestra Valuation Trend
Knowing Orchestra BioMed's actual value is paramount for traders when making sound investment determinations. Using both Orchestra BioMed's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Orchestra BioMed Total Value Analysis
Orchestra BioMed Holdings is now forecasted to have valuation of 104.37 M with market capitalization of 171.44 M, debt of 1.69 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Orchestra BioMed fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
104.37 M | 171.44 M | 1.69 M |
Orchestra BioMed Investor Information
About 22.0% of the company outstanding shares are owned by corporate insiders. The book value of Orchestra BioMed was now reported as 1.22. The company recorded a loss per share of 1.6. Orchestra BioMed Holdings had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Orchestra BioMed's historical financial statements, Orchestra BioMed Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Orchestra BioMed Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Orchestra BioMed has an asset utilization ratio of 2.9 percent. This suggests that the Company is making USD0.029 for each dollar of assets. An increasing asset utilization means that Orchestra BioMed Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Orchestra BioMed Ownership Allocation
Orchestra BioMed owns a total of 37.82 Million outstanding shares. Over half of Orchestra BioMed's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Orchestra BioMed Profitability Analysis
The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 2.45 M.About Orchestra BioMed Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Orchestra BioMed Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Orchestra BioMed Holdings based exclusively on its fundamental and basic technical indicators. By analyzing Orchestra BioMed's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Orchestra BioMed's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Orchestra BioMed. We calculate exposure to Orchestra BioMed's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Orchestra BioMed's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.3 M | 2.1 M | |
| Pretax Profit Margin | (20.47) | (19.44) | |
| Operating Profit Margin | (21.46) | (20.39) | |
| Net Loss | (20.47) | (19.44) | |
| Gross Profit Margin | 1.07 | 1.12 |
Orchestra BioMed Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 33.2 M |
Orchestra BioMed Current Valuation Indicators
Orchestra BioMed's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Orchestra BioMed's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Orchestra BioMed, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Orchestra BioMed's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Orchestra BioMed's worth.When determining whether Orchestra BioMed Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Orchestra BioMed's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Orchestra Biomed Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Orchestra Biomed Holdings Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share | Quarterly Revenue Growth 1.356 | Return On Assets | Return On Equity |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.